The company has participated in the national 11th Five-Year Plan major new drug development project “Key Technological Research on Chemical Modification of Polypeptide APIs and Industrial Scale Polypeptide Preparation”.
The national technology innovation fund for small and medium-sized enterprises “Nesiritide”, a new anti-heart failure Polypeptide drug, has entered the clinical research stage. In 2010, it was supported by the special funds of the emerging industries of Sichuan Economic Commission and the production of polypeptide drugs.
The above projects have completed the project construction content. It has more than 50 key technologies for the large-scale production of polypeptide API drugs and products on the market at home and abroad, with a single batch yield of up to kg level;
it has advanced international technologies such as large-scale production of thiocyclic Polypeptide, large-scale production of carbocyclic Polypeptide, complex polypeptide technology, and rapid synthesis of polypeptide technology; it has applied for 23 patents for invention;
it has obtained 5 patents for invention, and relies on its excellent synthesis of polypeptide. And the key technology of modification has become the leader of the domestic polypeptide API industry.